<DOC>
	<DOCNO>NCT00790101</DOCNO>
	<brief_summary>This multi-center , randomize , double-blind , double-dummy study design compare effect risedronate , raloxifene , placebo BMD , bone turnover marker , marker anabolic activity postmenopausal woman previously receive HRT .</brief_summary>
	<brief_title>Risedronate v Raloxifene Hormone Replacement Therapy Discontinuation</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<mesh_term>Raloxifene Hydrochloride</mesh_term>
	<criteria>Postmenopausal , ambulatory female , `` postmenopausal '' define absence menses least 12 continuous month ) In general good health determine medical history , physical examination , laboratory test LS spine BMD Tscore 1.0 2.4 , inclusive At least one analyzable BMD site hip ( left right ) LS spine ( least 3 measurable lumbar spine vertebra , without fracture sufficient degenerative disease ) Currently receive medication treatment prevention osteoporosis Had continuous HRT least 1 year prior enrollment . The HRT must end within 18 month prior baseline visit , subject must HRT medication least 3 month time baseline visit Subjects render menopausal surgical procedure age 55 65 year A history cancer within 10 year prior entry study , except relatively `` benign '' cure skin cancer basal squamous cell carcinoma A history hyperparathyroidism , hyperthyroidism , osteomalacia , metabolic bone disease within one year prior enrollment Any condition disease may interfere evaluation least 3 lumbar vertebra ( necessarily contiguous ) , determine screen radiograph radiologist central facility ( e.g. , confluent aortic calcification , severe osteoarthritis , spinal fusion , lumbar spine fracture ) Evidence clinically significant organic psychiatric disease history physical examination , opinion investigator would prevent patient complete study Markedly abnormal pretreatment laboratory find , opinion investigator , would prevent patient complete study A history use follow medication prior start study : Any bisphosphonate therapy Selective estrogen receptor modulators ( SERMs ) Parathyroid hormone Fluorides Calcitonin Calcitriol ( &gt; 1.5 mcg/week ) Corticosteroids chronic basis period equal great 3 month Received depot injection &gt; 10,000 IU Vitamin D past 12 month A history recurrent nephrolithiasis history one episode nephrolithiasis within 1 year study entry Serum creatinine &gt; 1.6 mg/dl Unable sit stand upright 30 minute take morning dose risedronate A history deep vein thrombosis coagulation disorder Severe hepatic insufficiency A history hypersensitivity raloxifene , risedronate , drug similar chemical structure Clinically relevant cardiovascular , hepatic , neurological , endocrine , major systemic disease make implementation protocol interpretation study result difficult Subjects find one vertebral fracture complete thoracic LS spine film Subjects experience low impact fracture relate osteopenia within two year baseline visit The information intend contain consideration relevant patient 's potential participation clinical trial</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>